Immunic sets Sept. 9 relapsing MS R&D webinar
Immunic, Inc. is holding a September 9, 2026 RMS R&D Day webinar and furnishing an investor presentation with extensive forward-looking statement caveats.
Rhea-AI Filing Summary
IMMUNIC, INC. (IMUX) announced that it is hosting a Relapsing Multiple Sclerosis Research and Development Day webinar on September 9, 2026, from 11:00 a.m. to 12:30 p.m. Eastern Time, where management will present updates on its programs, including vidofludimus calcium.
The company is using an investor presentation for this event, furnished as Exhibit 99.1. The materials are provided under a Regulation FD disclosure framework and are expressly stated as being furnished, not filed, and therefore are not subject to certain Exchange Act liabilities nor automatically incorporated into other SEC filings.
Immunic also includes an extensive cautionary note that characterizes statements about strategy, clinical development plans, timing of trials and regulatory approvals, cash runway, Nasdaq listing, and capitalization as forward-looking statements subject to substantial risks and uncertainties, directing investors to previously filed Risk Factors for more detail.
Positive
- None.
Negative
- None.
Insights
Analyzing...
8-K Event Classification
Key Figures
Key Terms
Regulation FD Disclosure regulatory
forward-looking statements regulatory
Private Securities Litigation Reform Act of 1995 regulatory
Risk Factors regulatory
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What event did IMUX announce in the September 9, 2026 Form 8-K?
When is the Immunic (IMUX) RMS R&D Day webinar scheduled and how long will it last?
What information is included in Immunic’s Exhibit 99.1 for IMUX?
Are the IMUX RMS R&D Day materials considered filed for liability purposes?
What forward-looking topics does Immunic (IMUX) highlight in this 8-K?
Where does Immunic (IMUX) direct investors for detailed risk factors?
AI-generated analysis. How Rhea-AI works. Not financial advice.
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM
CURRENT REPORT
Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):
(Exact name of registrant as specified in its charter)
| (State or other jurisdiction of incorporation) |
(Commission File Number) | (IRS Employer Identification No.) |
(Address of principal executive offices)
Registrant’s telephone number, including
area code:
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) | |
| Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) | |
| Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) | |
| Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class | Trading Symbol(s) | Name of exchange on which registered |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b2 of this chapter).
Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. Yes ☐ No ☐
Item 7.01. Regulation FD Disclosure
On September 9, 2026, Immunic, Inc. (the “Company” or “Immunic”) is hosting a Relapsing Multiple Sclerosis (RMS) Research and Development Day webinar (the “RMS R&D Day”). The RMS R&D Day will take place on Wednesday, September 9, 2026, from 11:00 a.m. to 12:30 p.m. ET via video conference. The Company intends to use a presentation during the RMS R&D Day (the “Presentation”) which is attached as Exhibit 99.1 to this Current Report on Form 8-K, and is incorporated herein by reference.
The information in Item 7.01 of this Current Report on Form 8-K and Exhibit 99.1 attached hereto shall not be deemed “filed” for the purposes of Section 18 of the Securities Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth therein.
Cautionary Note Regarding Forward-Looking Statements
Certain statements in this Current Report on Form 8-K and the Presentation are “forward-looking statements” that involve substantial risks and uncertainties for purposes of the safe harbor provided by the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical facts, included in this Current Report on Form 8-K, and the Presentation regarding strategy, future operations, future financial position, future revenue, projected expenses, sufficiency of cash and cash runway, expected timing, development and results of clinical trials, prospects, plans and objectives of management are forward-looking statements. Examples of such statements include, but are not limited to, statements relating to Immunic's development programs and the targeted diseases; the potential for vidofludimus calcium to safely and effectively target diseases; preclinical and clinical data for vidofludimus calcium; the feasibility of advancing vidofludimus calcium to a confirmatory phase 3 clinical trial in progressive multiple sclerosis; the timing of current and future clinical trials, anticipated clinical milestones and regulatory approvals; the nature, strategy and focus of the company and further updates with respect thereto; the development and commercial potential of any product candidates of the company; Immunic’s continued listing on The Nasdaq Capital Market; and expectations regarding the capitalization, resources and ownership structure of the company and its executive and board structure. Immunic may not actually achieve the plans, carry out the intentions or meet the expectations or projections disclosed in the forward-looking statements and you should not place undue reliance on these forward-looking statements. Such statements are based on management’s current expectations and involve substantial risks and uncertainties. Actual results and performance could differ materially from those projected in the forward-looking statements as a result of many factors, including, without limitation, increasing inflation, tariffs and macroeconomics trends, impacts of the Ukraine - Russia conflict and the conflict in the Middle East on planned and ongoing clinical trials, risks and uncertainties associated with the ability to project future cash utilization and reserves needed for contingent future liabilities and business operations, the availability of sufficient financial and other resources to meet business objectives and operational requirements, the fact that the results of earlier preclinical studies and clinical trials may not be predictive of future clinical trial results, any changes to the size of the target markets for the company’s products or product candidates, the protection and market exclusivity provided by Immunic’s intellectual property, risks related to the drug development and the regulatory approval process and the impact of competitive products and technological changes. A further list and descriptions of these risks, uncertainties and other factors can be found in the section captioned “Risk Factors,” in the company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2025, filed with the SEC on February 26, 2026, and in the company’s subsequent filings with the SEC. Copies of these filings are available online at www.sec.gov or ir.imux.com/sec-filings. Any forward-looking statement made in this Current Report on Form 8-K and the Presentation speaks only as of the date of this Current Report on Form 8-K, and the Presentation. Immunic disclaims any intent or obligation to update these forward-looking statements to reflect events or circumstances that exist after the date on which they were made. Immunic expressly disclaims all liability in respect to actions taken or not taken based on any or all of the contents of this Current Report on Form 8-K and the Presentation.
Item 9.01. Financial Statements and Exhibits.
| Exhibit | Description |
| 99.1 | Presentation, dated September 9, 2026 |
| 104 | Cover Page Interactive Data File (formatted as Inline XBRL). |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto duly authorized.
| Dated: September 9, 2026 | Immunic, Inc. | |
| By: | /s/ Erik Lundgren | |
| Erik Lundgren | ||
| Chief Executive Officer | ||
